Calidi Biotherapeutics (CLDI) Free Cash Flow (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Free Cash Flow of -$5.1 million for Q4 2025, up 6.41% year-over-year from -$4.8 million in Q4 2024, and down 19.11% quarter-over-quarter from -$4.3 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Free Cash Flow (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$5.1 million for Q4 2025.
- In Q4 2025, Free Cash Flow rose 6.41% year-over-year to -$5.1 million; the TTM figure through Dec 2025 stood at -$21.4 million (down 8.68% YoY), while the FY2025 annual figure was -$21.4 million, down 8.68% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$5.1 million, down from -$4.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$268679.0 in Q2 2022, with the low at -$14.0 million in Q3 2023.
- The 4-year median for Free Cash Flow is -$5.0 million (2023), against an average of -$5.1 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow sank 1742.35% in 2023, then surged 64.64% in 2024.
- Calidi Biotherapeutics' Free Cash Flow stood at -$4.0 million in 2022, then tumbled by 30.2% to -$5.3 million in 2023, then decreased by 3.27% to -$5.4 million in 2024, then gained by 6.41% to -$5.1 million in 2025.
- Business Quant data shows CLDI's Free Cash Flow at -$5.1 million in Q4 2025, -$4.3 million in Q3 2025, and -$4.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.08 Mn |
| Dec 31, 2025 | -5.08 Mn |
| Sep 30, 2025 | -4.27 Mn |
| Sep 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Mar 31, 2025 | -7.14 Mn |
| Mar 31, 2025 | -7.14 Mn |
| Dec 31, 2024 | -5.43 Mn |
| Dec 31, 2024 | -5.43 Mn |
| Sep 30, 2024 | -4.95 Mn |
| Sep 30, 2024 | -4.95 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | -5.26 Mn |
| Dec 31, 2023 | -5.26 Mn |
| Sep 30, 2023 | -14.01 Mn |
| Sep 30, 2023 | -14.01 Mn |